The Elemento Lab is affiliated with Weill Cornell Medicine's Englander Institute for Precision Medicine (EIPM), where Olivier Elemento, Ph.D., serves as Director.
The Englander Institute for Precision Medicine (EIPM) is a translational research hub using precision medicine tools, such as genetics, genomic sequencing, and clinical data to improve patients’ healthcare. Our multidisciplinary team of basic scientists, pathologists, molecular biologists, and computational biologists have successfully translated research findings into clinical practice. We have developed highly innovative tools and technologies to better study how cancer and other diseases develop, change, and respond to various therapies and drug combinations. We are revolutionizing healthcare to better predict, diagnose, treat and prevent disease.
With the creation of the Institute for Computational Biomedicine (ICB), Weill Medical College of Cornell University will realize the full potential of mathematics and computation to enhance the study of medicine. Employing the tools of applied mathematics and computer-based technologies will enable physician-scientists to attack complex medical problems formerly beyond their reach.
The Meyer Cancer Center is a collaborative, multidisciplinary research enterprise located at Weill Cornell Medical College, in affiliation with NewYork-Presbyterian Hospital. Equipped with the latest state-of-the-art technologies, nearly 250 basic, translational and clinical researchers from Weill Cornell and Cornell University’s Ithaca campus work together with colleagues at other institutions – including Memorial Sloan Kettering, Columbia University, Rockefeller University and New York Methodist Hospital – to take fundamental discoveries from bench to bedside, and back again. The Center’s mission is to ensure that patients can have immediate access to emerging new therapies in a supportive and caring environment, while training future researchers and recruiting leaders in cancer research and clinical care.
Weill Cornell’s CTSC is one of more than 60 federally supported programs nationwide that similarly prioritize collaboration, mentorship and community participation. Since it was founded a decade ago, Weill Cornell Medicine’s CTSC has focused on advancing translational science discoveries across a broad spectrum of clinical disciplines and diseases. The CTSC’s achievements are exemplified in its educational and community-based efforts and has emerged as a premier hub for scientific discovery at Weill Cornell and a full-service home for translational research.
The New York Genome Center (NYGC) is dedicated to advancing the field of genomic research and clinical genetics, and acknowledges that the exchange of ideas among researchers, both within and outside the NYGC, is essential for the development of new genomic technologies and advancing basic science and the understanding of the genetic basis of human diseases. To that end, the NYGC provides Affiliate Memberships to external academic researchers who have a significant interest in and commitment to the scientific life and work of the NYGC, and will contribute to and benefit from the NYGC’s mission. As a NYGC affiliate member, Dr. Elemento contributes to the NYGC’s Genome Center Cancer Group (GCCG), and the computational working group for Polyethnic-1000, a project to study cancer in New York’s ethnically diverse, underserved patient populations. With Dr. Harold Varmus, he serves as co-chair of the multi-institutional Very Rare Cancer Consortium, a research cohort focused on understanding the genetic causes for rare, understudied cancers.
Volastra Therapeutics is a biotechnology company focused on developing novel therapies for patients with metastatic cancers by exploiting unique insights into chromosomal instability. Founded by Drs. Lewis Cantley and Olivier Elemento from Weill Cornell Medicine and Dr. Samuel Bakhoum from Memorial Sloan Kettering Cancer Center, Volastra is quickly advancing multiple programs towards the clinic. Volastra Therapeutics’ operations are located at Johnson & Johnson Innovation, JLABS at New York City (JLABS @ NYC).
Scientific Advisor and Co-Founder
OneThree Biotech is a New York based startup that uses a biology-driven artificial intelligence (AI) platform to optimize pre-clinical drug discovery and development. The company was founded by Neel S. Madhukar, Ph.D., Olivier Elemento, Ph.D., Coryandar Gilvary, Ph.D., and Bradlay Pryde. They were selected as part of the 2020 class of startups for Grand Central Tech and the platform has won awards such as "Most Innovative Technology" award at the 2019 InnoHubei International Science and Technology Innovation and Entrepreneurship Competition. The technology has also been validated through a Phase 2 trial in H3K27M glioblastoma.
A partnership between New York City and its universities, RLab is the nation’s first city-funded center for research, education and entrepreneurship in virtual and augmented reality and related technologies. With 16,500 square feet of co-working space, classrooms, studios and more in the Brooklyn Navy Yard, RLab will host a variety of programs and events – from classes and trainings, to startup accelerators, corporate innovation tours, and much more. NYCEDC and the Mayor's Office of Media and Entertainment selected NYU Tandon School of Engineering as the administering institution and a consortium of participating universities, including Columbia University, CUNY, and The New School to manage and operate the RLab space, along with a workforce development center at CUNY Lehman College in the Bronx. The new multi-university center is critical to the City’s plans to establish New York City as the next global leader in immersive technologies and will create hundreds of new jobs in the field.